Published in AIDS Res Hum Retroviruses on December 10, 2000
Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem (2008) 1.80
Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol (2011) 1.09
Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J (2006) 0.96
Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol (2001) 0.94
Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J (2006) 0.87
Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals. PLoS One (2014) 0.81
Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis. Br J Clin Pharmacol (2011) 0.80
Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine. Arch Toxicol (2010) 0.79
Cutaneous drug hypersensitivity: immunological and genetic perspective. Indian J Dermatol (2011) 0.75
Immunogenicity of trimethoprim/sulfamethoxazole in a macaque model of HIV infection. Toxicology (2016) 0.75
Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: A meta-analysis. World J Virol (2015) 0.75
Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk. Pharmacol Res Perspect (2017) 0.75
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42
Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol (2006) 3.56
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
Adverse drug reactions. BMJ (1998) 3.25
Intraoperative bacterial contamination in operations for joint replacement. J Bone Joint Surg Br (1999) 3.07
Failure of chloroquine and proguanil prophylaxis in travellers to Kenya. Lancet (1991) 3.03
A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci (2000) 2.98
Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res (2001) 2.69
Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J (2006) 2.40
The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors. Oncol Nurs Forum (1998) 2.39
HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther (2012) 2.36
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther (2012) 2.10
4-Aminoquinolines--past, present, and future: a chemical perspective. Pharmacol Ther (1998) 2.00
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia (2009) 1.99
Evaluations of aesthetic results in breast reconstruction: an analysis of reliability. Ann Plast Surg (1996) 1.90
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem (1978) 1.90
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J (2006) 1.87
Rifampicin and vitamin D metabolism. Clin Pharmacol Ther (1980) 1.78
Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol (2001) 1.77
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses? Clin Pharmacol Ther (2007) 1.70
Leucocyte esterase-nitrite screening method for pyuria and bacteriuria. J Clin Pathol (1985) 1.67
Determinants of patient satisfaction in postmastectomy breast reconstruction. Plast Reconstr Surg (2000) 1.67
Utility of PCR in diagnosing pulmonary tuberculosis. J Clin Microbiol (1996) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther (2013) 1.61
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J (2006) 1.59
Differential detection of transmissible gastroenteritis virus and porcine epidemic diarrhea virus by duplex RT-PCR. J Vet Diagn Invest (2001) 1.59
Tuberculous pericarditis confirmed by DNA amplification. Lancet (1991) 1.54
Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.53
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther (1981) 1.52
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther (2013) 1.49
Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. Vaccine (2003) 1.47
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther (2007) 1.47
Drug disposition and drug hypersensitivity. Biochem Pharmacol (1987) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
Isolation and phylogenetic analysis of H1N1 swine influenza virus isolated in Korea. Virus Res (2006) 1.45
Herbal medicines. Postgrad Med J (2003) 1.45
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Diagnosis of silicone gel breast implant rupture by ultrasonography. Plast Reconstr Surg (1996) 1.43
Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 1.43
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS (1996) 1.41
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol (2003) 1.35
4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem (1996) 1.35
The burden of alcohol misuse on an inner-city general hospital. QJM (2000) 1.31
An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol (1988) 1.29
Use of Roche AMPLICOR Mycobacterium tuberculosis PCR in early diagnosis of tuberculous meningitis. J Clin Microbiol (1998) 1.29
Application of scanning electron microscopy in assessing the prevalence of some Setaria species in Korean cattle. Korean J Parasitol (1994) 1.27
Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol (1989) 1.27
Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther (2006) 1.27
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol (1986) 1.26
Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol (1981) 1.26
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol (1980) 1.21
Specialist nurse reporting of adverse drug reactions. Prof Nurse (2000) 1.19
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1984) 1.19
Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element. J Virol (1995) 1.19
Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol (2001) 1.19
Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol (1984) 1.19
How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol (2011) 1.19
One-step multiplex RT-PCR for detection and subtyping of swine influenza H1, H3, N1, N2 viruses in clinical samples using a dual priming oligonucleotide (DPO) system. J Virol Methods (2008) 1.18
Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol (1983) 1.17
Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol Biochem Parasitol (1996) 1.15
Effect of chloroquine and primaquine on antipyrine metabolism. Br J Clin Pharmacol (1983) 1.13
Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol (1992) 1.13
Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol (2000) 1.13
Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med (1986) 1.12
Interspecies transmission of the canine influenza H3N2 virus to domestic cats in South Korea, 2010. J Gen Virol (2011) 1.10
Outcome of varicella pneumonitis in immunocompetent adults requiring treatment in a high dependency unit. J Infect (2001) 1.10
A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol (1982) 1.10
Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther (1982) 1.10
The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. Contraception (1981) 1.09
Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther (2000) 1.09
Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes. Br J Pharmacol (1998) 1.09
Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings]. Br J Clin Pharmacol (1978) 1.09
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J (2010) 1.07
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol (1988) 1.07
Predictors of patient satisfaction in an outpatient plastic surgery clinic. Ann Plast Surg (1999) 1.07
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther (2012) 1.06
Difenacoum (Neosorexa) poisoning. Br Med J (Clin Res Ed) (1982) 1.06
Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther (1996) 1.06
The effect of enzyme induction on diazepam metabolism in man. Br J Clin Pharmacol (1979) 1.05
A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther (2011) 1.05
Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. Br J Clin Pharmacol (1981) 1.05
Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol (2001) 1.05
A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. Br J Pharmacol (1985) 1.04
[Isolation and identification of Cryptosporidium from various animals in Korea. I. Prevalence of Cryptosporidium in various animals]. Kisaengchunghak Chapchi (1991) 1.04
Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J (2009) 1.04
Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol (1986) 1.04
Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf (2000) 1.03
A study of anal intraepithelial neoplasia in HIV positive homosexual men. Sex Transm Infect (1999) 1.03